What happens when four longevity scientists discover that they can reverse the age of your skin? OneSkin: a breakthrough line of skin health products powered by longevity science to address the root causes of aging.
Reference Lab
Feb 2nd, 2023
Born in the Lab
Our story began in a doctorate lab in Brazil, where our founding team met while completing their PhDs. Carolina, Alessandra, Mariana, and Juliana bonded over their shared interest in longevity science and their dreams of making age-related diseases a thing of the past.
Together, the group explored their shared interest in skinโand its potential as the bodyโs largest organ to unlock the secrets to whole-system longevity. Our founders understood that if they could effectively slow the rate of skin aging, they could promote overall body healthโcomplementing longevity practices and personalized medicine to optimize human living.
Our Origins as a Research Company
A few patents and papers later, our founders joined forces to start a research company dedicated to testing the anti-aging efficacy of topical skincare using their breakthrough invention, MolClock, the first ever skin-specific molecular clock. This advanced algorithm identifies the skinโs molecular age based on DNA methylation โ an important indicator of overall skin health. By analyzing skin age with MolClock before and after the application of topical products, our team discovered how to quantify the efficacy of skin products at the molecular level.
The team put thousands of ingredients and cosmetic formulations to the test. What they discovered was shocking: not only are most skincare products ineffective, many actually accelerate skin aging at the cellular level. While the team never set out to create skin products, they knew they had to get involvedโformulating a new kind of skin care that actually lived up to their high scientific standards.
Together, they embarked on a mission they never intended to pursue, but haven't stopped chasing since: revolutionizing the skin care industry by developing proven products that actually reverse aging at the molecular level.
Discovering the OS-01 Peptide
To revolutionize the way people care for their skin, our team needed to discover a technology unlike anything on the market. So, they got to work doing what they do best: identifying new molecules and analyzing their effects on the skin at the cellular level. While many skincare companies make claims about aging, OneSkin is the first company that replicates skin aging in the lab to validate the efficacy of our products at the cellular level. After analyzing thousands of peptides, our founders discovered OS-01: the first peptide proven to reverse aging on the molecular level by reducing the accumulation of senescent cells in lab-grown ex vivo human skin models. Learn more about cellular senescence here.
Looking to the Future
Thanks to our founders, science is in the OneSkin DNA. Most โscience-backedโ skincare companies are led by marketing teams that outsource their research to external labs. OneSkin is different. Weโre led by scientists who run our end-to-end R&D process in-house and adhere to the strict rigor of the scientific process. The result? Research first. Products second. Data-validated claims always.
Fueled by our passion for science and our love of life, weโre on a mission to revolutionize the way humans experience aging.
ย
MEETย THE TEAM
01Carolina Reis Oliveira, PhD; Co-Founder and Chief Executive Officer (CEO)
- Ph.D. in Immunology, Federal University of Minas Gerais in collaboration with Rutgers University
- Alumnus of IndieBio, the world's leading biotechnology accelerator
- Co-inventor of three patents
02 Alessandra Zonari, PhD; Co-Founder and Chief Scientific Officer (CSO)
- PhD in skin regeneration and tissue engineering, Federal University of Minas Gerais in collaboration with 3Bโs Research Group in Portugal
- Second post-doctoral, University of Coimbra, Portugal
- Co-inventor of three patents
- Author of 20 peer-reviewed papers published in scientific journals
03 Mariana Boroni, PhD; Co-Founder and Head of Bioinformatics
- PhD in bioinformatics with an emphasis in genomics, Federal University of Minas Gerais with post-doctorate at the Gene Center at LMU, Germany.
- Head of the Bioinformatics and Computational Biology Lab, Brazilian National Cancer Institute (INCA)
- Co-inventor of four patents
- Author of 26 peer-reviewed papers published in scientific journals
04 Juliana Carvalho, PhD; Co-Founder
- PhD in molecular biology, Federal University of Minas Gerais
- Professor of Pathology, Catholic University of Brasilia
- Co-inventor of four patents
- Author of 34 peer-reviewed papers published in scientific journals